Avastin Follow-Up: Info from the FDA

By Rachel Walden |

On Friday, Christine posted, FDA Moves to Revoke Approval of Popular Breast Cancer Drug, with the news of and reactions to the FDA’s recent decision that Avastin (bevacizumab) should no longer be approved for use for breast cancer because “the agency has determined that the risks of the drug outweigh the benefits for this use.”

The FDA has posted a site with additional details about the recommendation, including their decision memo explaining the agency’s rationale, press release, questions and answers, and letter to the breast cancer community.

Comments for this post are closed.